Biopharmaceutical company Takeda (TSE:4502) (NYSE:TAK) announced on Monday that HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] has been approved in Europe as maintenance therapy in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) after stabilisation with intravenous immunoglobulin therapy (IVIG).
HyQvia offers a flexible treatment option, allowing patients to infuse up to once monthly, either at home or in-office. The first and only facilitated subcutaneous immunoglobulin (fSCIG) for CIDP, HyQvia aids in dispersion and absorption of large immunoglobulin volumes in the subcutaneous space between the skin and the muscle.
The European Commission's approval was based on Phase 3 data showing a significant reduction in CIDP relapse rate with HyQvia versus placebo.
Gilead expands global access to lenacapavir for HIV prevention
Alume Biosciences names new chief commercial officer
genedrive plc secures initial UK order for Genedrive CYP2C19-ID Kit
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Oxford BioDynamics announces opening of clinical testing facility in UK for prostate screening test
Micron Biomedical names new scientific advisor to CEO
China accepts GSK's Shingrix application for at-risk adults
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Allurion's Gastric Balloon introduced at Somerset NHS Foundation Trust for pre-surgical weight loss